The prostate-specific antigen screening conundrum: Examining the evidence

Seminars in Oncology Nursing

Volumn 27, Issue 4, 2011, Pages 251-259

  O'Rourke, Maureen E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Evidence; Prostate specific antigen (PSA); Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; EVIDENCE BASED MEDICINE; HUMAN; MALE; MIDDLE AGED; NURSING; PRACTICE GUIDELINE; PROSTATE TUMOR; UNITED STATES;

ADULT; AGED; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 80055089606     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2011.07.003     Document Type: Article

References (39)

1. Dickens C. Great expectations 2004, Pocket Books, NY, pp 412.
2. Carson C.C. Carcinoma of the prostate: Overview of the most common malignancy in men. NC Med J 2006, 67:122-127.
3. Draisma G., Boer R., Otto S.J., et al. Lead times and over detection due to prostate specific antigen screening: estimates from European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003, 95:868-878.
4. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
5. Chang S.L., Harshman L.C., Presti J.C. Impact of common medications on serum total prostate specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010, 28:3951-3957.
6. Choi Y.K., Cho S.Y., Cho I.R. The different reduction rate of prostate-specific antigen in dutasteride and finasteride. Korean J Urol 2010, 51:704-708.
7. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age -specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996, 335:304-310.
8. Brawer M.K. Prostate specific antigen: current status. CA Cancer J Clin 1999, 49:264-281.
9. Arcangeli C.G., Ornstein D.K., Keetch D.W., et al. Prostate specific antigen as a screening test for prostate cancer. Urol Clin North Am 1997, 24:299-306.
10. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges. JAMA 1993, 270:860-864.
11. Moul J.W., Sesterhenn I.A., Connelly R.R., et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995, 274:1277-1281.
12. American Cancer Society. Cancer facts and figures for African Americans 2011-2012. Available at: (accessed March 12, 2011). http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027765.pdf.
13. National Guideline Clearinghouse (NGC). Guideline synthesis: screening for prostate cancer. National Guideline Clearinghouse (NGC). Rockville, MD; 1998 (revised 2010 May). Available at: (accessed 23 March, 2011). http://www.guideline.gov/syntheses/synthesis.aspx?id=16398%26search=prostate+cancer.
14. American Urological Association (AUA). Prostate-specific antigen best practice statement: 2009 update. Linthicum, MD; American Urological Association Education and Research, Inc.; 2009. Available at: (accessed March 6, 2011). http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf.
15. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD; National Cancer Institute. Available at (accessed March 12, 2011). http://seer.cancer.gov/csr/1975_2004/.
16. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD; National Cancer Institute. Available at: (accessed March 12, 2011). http://seer.cancer.gov/csr/1973_1999/prostate.pdf.
17. Martin R.M. Prostate cancer is omnipresent, but should we screen for it?. Int J Epidemiol 2007, 36:278-281.
18. Screening for prostate cancer in U.S. men. Am J Prev Med 2008, 34:164-170. American College of Preventive Medicine (ACPM).
19. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:185-191. U.S. Preventive Services Task Force (USPSTF).
20. Kawachi M.H., Bahnson R.R., Barry M., et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw 2010, 8:240-262.
21. Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European Union. November 1999. Available at: (accessed March 28, 2011). http://ec.europa.eu/health/ph_determinants/genetics/cancer_screening_en.pdf.
22. Council of the European Union. Council recommendation of 2 December 2003 on cancer screening. Document # 32003H0878. Available at: (accessed March 28, 2011). http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32003H0878:EN:HTML.
23. Feightner JW. Screening for prostate cancer. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa; Health Canada; 1994: pp 812-23. Available at: (accessed March 28, 2011). http://www.canadiantaskforce.ca/index.html.
24. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 7th ed. Victoria, Australia; 2009. Available at: (accessed March 27, 2011). http://www.racgp.org.au/Content/NavigationMenu/ClinicalResources/RACGPGuidelines/TheRedBook/redbook_7th_edition_May_2009.pdf.
25. Hamashina C., Nakayama T., Sagawa M., et al. Japanese guideline for prostate cancer screening. Jpn J Clin Oncol 2009, 39:339-351.
26. UK National Screening Committee. The UK NSC policy on Prostate cancer screening/PSA testing in men over the age of 50. Available at: (accessed March 13, 2011). http://www.screening.nhs.uk/prostatecancer.
27. Wolf M., Wender C., Etzioni R., et al. American Cancer Society guideline for the early detection of prostate cancer. Update 2010. CA Cancer J Clin 2010, 60:70-98.
28. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
29. Andriole G.L., Crawford E.D., Grubb R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
30. Jegu J., Tretarre B., Grosclaude P., et al. Results and participation factors to the European Randomized Study of Screening for Prostate Cancer (ERSPC) with prostate specific antigen: French departments of Tam Herault. Prog Urol 2009, 19:487-498.
31. Hugosson J., Carlsson S., Aus G., et al. Mortality results form the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725-732.
32. Labrie F., Candas B., Cusan L., et al. Screening decreases prostate cancer mortality: 11 year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004, 59:311-318.
33. Varenhorst E., Carlsson P., Capik E., et al. Repeated screening of carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol 1992, 31:815-821.
34. Djulbegovic M., Beyth R.J., Neuberger M.M., et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010, 341:c4543. [abstract].
35. Sandblom G., Varenhorst E., Rosell J., et al. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011, 342:d1539. [abstract].
36. Guyatt G.H., Oxman A.D., Kunz R., et al. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008, 336:995-998.
37. Ilic D., O'Connor D., Green S., et al. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 2011, 107:882-991.
38. Illic D., O'Connor D., Green S., et al. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. Art No: CD004720, doi: 10.1002/14651858. CD004720.pub2.
39. Donovan J., Handy F., Neal D. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess 2003, 7:1-81.